LEXEO THERAPEUTICS INC. - COMMON STOCK

Lexeo Therapeutics Reports First Quarter 2025 Financial Results and Operational Highlights

12 май 2025 04:00:00 Источник Nasdaq GlobeNewswire

Lexeo Therapeutics to Present New CMC Data at the 28th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting

01 май 2025 06:16:04 Источник Nasdaq GlobeNewswire

Lexeo Therapeutics Announces Positive Interim Phase 1/2 Data for LX2006 in Friedreich Ataxia Cardiomyopathy Supporting Advancement to Registrational Study

07 апр 2025 03:00:00 Источник Nasdaq GlobeNewswire

Lexeo Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights

24 мар 2025 04:00:00 Источник Nasdaq GlobeNewswire

Lexeo Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

07 янв 2025 04:30:00 Источник Nasdaq GlobeNewswire

Lexeo Therapeutics Appoints Kyle Rasbach as Chief Financial Officer

19 дек 2024 04:00:00 Источник Nasdaq GlobeNewswire

Lexeo Therapeutics Provides Update on Cardiac Portfolio and Reports Third Quarter 2024 Financial Results

13 ноя 2024 04:30:00 Источник Nasdaq GlobeNewswire

Lexeo Therapeutics Announces Positive Interim Data for LX1001, First-Ever Gene Therapy to Impact the Underlying Genetic Cause of APOE4-Associated Alzheimer’s Disease, at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference

30 окт 2024 03:14:00 Источник Nasdaq GlobeNewswire

Lexeo Therapeutics to Present New Interim Data from Phase 1/2 Trial of LX1001 at the Clinical Trials on Alzheimer’s Disease (CTAD) 2024 Conference

22 окт 2024 04:30:00 Источник Nasdaq GlobeNewswire

Lexeo Therapeutics to Participate in Upcoming Investor Conferences

05 сен 2024 04:30:00 Источник Nasdaq GlobeNewswire

Lexeo Therapeutics Reports Second Quarter 2024 Financial Results and Operational Highlights

12 авг 2024 04:00:00 Источник Nasdaq GlobeNewswire

Lexeo Therapeutics Announces Positive Interim Phase 1/2 Clinical Data of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy

15 июл 2024 03:00:00 Источник Nasdaq GlobeNewswire

Lexeo Therapeutics Announces Investor Webcast to Report Interim Phase 1/2 Clinical Data of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy on Monday, July 15, 2024

11 июл 2024 05:00:00 Источник Nasdaq GlobeNewswire

Lexeo Therapeutics Appoints Tim Van Hauwermeiren to its Board of Directors

08 июл 2024 04:00:00 Источник Nasdaq GlobeNewswire

Lexeo Therapeutics Reports First Quarter 2024 Financial Results and Operational Highlights

09 май 2024 04:00:00 Источник Nasdaq GlobeNewswire

Lexeo Therapeutics to Participate in Upcoming Investor Conferences

07 май 2024 04:30:00 Источник Nasdaq GlobeNewswire

Lexeo Therapeutics Announces License Agreement to Accelerate Development of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy

22 апр 2024 04:30:00 Источник Nasdaq GlobeNewswire

Lexeo Therapeutics Granted FDA Fast Track Designation for LX2006, an AAV-Based Gene Therapy Candidate for the Treatment of Friedreich’s Ataxia Cardiomyopathy

16 апр 2024 04:30:00 Источник Nasdaq GlobeNewswire

Lexeo Therapeutics Announces Closing of Oversubscribed $95.0 Million Equity Financing

13 мар 2024 13:22:39 Источник Nasdaq GlobeNewswire

Lexeo Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights

11 мар 2024 04:42:39 Источник Nasdaq GlobeNewswire